|
1
|
Sanoski CA: Clinical, economic, and
quality of life impact of atrial fibrillation. J Manag Care Pharm.
15(6 Suppl B): S4–S9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen PS, Chen LS, Fishbein MC, Lin SF and
Nattel S: Role of the autonomic nervous system in atrial
fibrillation: Pathophysiology and therapy. Circ Res. 114:1500–1515.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Denham NC, Pearman CM, Caldwell JL,
Madders GWP, Eisner DA, Trafford AW and Dibb KM: Calcium in the
pathophysiology of atrial fibrillation and heart failure. Front
Physiol. 9:13802018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pellman J and Sheikh F: Atrial
fibrillation: Mechanisms, therapeutics, and future directions.
Compr Physiol. 5:649–665. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Polyakova V, Miyagawa S, Szalay Z, Risteli
J and Kostin S: Atrial extracellular matrix remodelling in patients
with atrial fibrillation. J Cell Mol Med. 12:189–208. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nattel S: Molecular and cellular
mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin
Electrophysiol. 3:425–435. 2017. View Article : Google Scholar
|
|
7
|
de Boer RA, De Keulenaer G, Bauersachs J,
Brutsaert D, Cleland JG, Diez J, Du XJ, Ford P, Heinzel FR, Lipson
KE, et al: Towards better definition, quantification and treatment
of fibrosis in heart failure. A scientific roadmap by the committee
of translational research of the heart failure association (HFA) of
the European society of cardiology. Eur J Heart Fail. 21:272–285.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kong P, Christia P and Frangogiannis NG:
The pathogenesis of cardiac fibrosis. Cell Mol Life Sc. 71:549–574.
2014. View Article : Google Scholar
|
|
9
|
Fan D, Takawale A, Lee J and Kassiri Z:
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling
in heart disease. Fibrogenesis Tissue Repair. 5:152012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rog-Zielinska EA, Norris RA, Kohl P and
Markwald R: The living scar-cardiac fibroblasts and the injured
heart. Trends Mol Med. 22:99–114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kohl P and Gourdie RG: Fibroblast-myocyte
electrotonic coupling: Does it occur in native cardiac tissue? J
Mol Cell Cardiol. 70:37–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ongstad E and Kohl P: Fibroblast-myocyte
coupling in the heart: Potential relevance for therapeutic
interventions. J Mol Cell Cardiol. 91:238–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nguyen TP, Qu Z and Weiss JN: Cardiac
fibrosis and arrhythmogenesis: The road to repair is paved with
perils. J Mol Cell Cardiol. 70:83–91. 2014. View Article : Google Scholar
|
|
14
|
Krul SPJ, Berger WR, Smit NW, van
Amersfoorth SC, Driessen AH, van Boven WJ, Fiolet JW, van Ginneken
AC, van der Wal AC, de Bakker JM, et al: Atrial fibrosis and
conduction slowing in the left atrial appendage of patients
undergoing thoracoscopic surgical pulmonary vein isolation for
atrial fibrillation. Circ Arrhythm Electrophysiol. 8:288–295. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nattel S: Electrical coupling between
cardiomyocytes and fibroblasts: Experimental testing of a
challenging and important concept. Cardiovasc Res. 114:349–352.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perbellini F, Watson SA, Bardi I and
Terracciano CM: Heterocellularity and cellular cross-talk in the
cardiovascular system. Front Cardiovasc Med. 5:1432018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT,
D'Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA
and Tallquist MD: Revisiting cardiac cellular composition. Circ
Res. 118:400–409. 2016. View Article : Google Scholar :
|
|
18
|
Zhou P and Pu WT: Recounting cardiac
cellular composition. Circ Res. 118:368–370. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma Y, de Castro Brás LE, Toba H, Iyer RP,
Hall ME, Winniford MD, Lange RA, Tyagi SC and Lindsey ML:
Myofibroblasts and the extracellular matrix network in
post-myocardial infarction cardiac remodeling. Pflugers Arch.
466:1113–127. 2014.PubMed/NCBI
|
|
20
|
Burstein B, Libby E, Calderone A and
Nattel S: Differential behaviors of atrial versus ventricular
fibroblasts: A potential role for platelet-derived growth factor in
atrial-ventricular remodeling differences. Circulation.
117:1630–1641. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moore-Morris T, Cattaneo P, Puceat M and
Evans SM: Origins of cardiac fibroblasts. J Mol Cell Cardiol.
91:1–5. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krenning G, Zeisberg EM and Kalluri R: The
origin of fibroblasts and mechanism of cardiac fibrosis. J Cell
Physiol. 225:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moore-Morris T, Guimarães-Camboa N,
Banerjee I, Zambon AC, Kisseleva T, Velayoudon A, Stallcup WB, Gu
Y, Dalton ND, Cedenilla M, et al: Resident fibroblast lineages
mediate pressure overload-induced cardiac fibrosis. J Clin Invest.
124:2921–2934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ali SR, Ranjbarvaziri S, Talkhabi M, Zhao
P, Subat A, Hojjat A, Kamran P, Müller AM, Volz KS, Tang Z, et al:
Developmental heterogeneity of cardiac fibroblasts does not predict
pathological proliferation and activation. Circ Res. 115:625–635.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lajiness JD and Conway SJ: The dynamic
role of cardiac fibroblasts in development and disease. J
Cardiovasc Transl Res. 5:739–748. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Travers JG, Kamal FA, Robbins J, Yutzey KE
and Blaxall BC: Cardiac fibrosis: The fibroblast awakens. Circ Res.
118:1021–1040. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim SK, Park JH, Kim JY, Choi JI, Joung B,
Lee MH, Kim SS, Kim YH and Pak HN: High plasma concentrations of
transforming growth factor-β and tissue inhibitor of
metalloproteinase-1: Potential non-invasive predictors for
electroanatomical remodeling of atrium in patients with
non-valvular atrial fibrillation. Circ J. 75:557–564. 2011.
View Article : Google Scholar
|
|
28
|
Goudis CA, Kallergis EM and Vardas PE:
Extracellular matrix alterations in the atria: Insights into the
mechanisms and perpetuation of atrial fibrillation. Europace.
14:623–630. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frangogiannis NG: The extracellular matrix
in myocardial injury, repair, and remodeling. J Clin Invest.
127:1600–1612. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rienks M, Papageorgiou AP, Frangogiannis
NG and Heymans S: Myocardial extracellular matrix: An ever-changing
and diverse entity. Circ Res. 114:872–888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu X, Meng L, Shi Q, Liu S, Cui C, Hu S
and Wei Y: Dermatopontin promotes adhesion, spreading and migration
of cardiac fibroblasts in vitro. Matrix Biol. 32:23–31. 2013.
View Article : Google Scholar
|
|
32
|
López B, González A, Ravassa S, Beaumont
J, Moreno MU, San José G, Querejeta R and Díez J: Circulating
biomarkers of myocardial fibrosis: The need for a reappraisal. J Am
Coll Cardiol. 65:2449–2456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Richter B, Gwechenberger M, Socas A, Zorn
G, Albinni S, Marx M, Wolf F, Bergler-Klein J, Loewe C, Bieglmayer
C, et al: Time course of markers of tissue repair after ablation of
atrial fibrillation and their relation to left atrial structural
changes and clinical ablation outcome. Int J Cardiol. 152:231–236.
2011. View Article : Google Scholar
|
|
34
|
Kawamura M, Munetsugu Y, Kawasaki S,
Onishi K, Onuma Y, Kikuchi M, Tanno K and Kobayashi Y: Type III
procollagen-N-peptide as a predictor of persistent atrial
fibrillation recurrence after cardioversion. Europace.
14:1719–1725. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Spinale FG: Myocardial matrix remodeling
and the matrix metalloproteinases: Influence on cardiac form and
function. Physiol Rev. 87:1285–1342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li M, Yang G, Xie B, Babu K and Huang C:
Changes in matrix metalloproteinase-9 levels during progression of
atrial fibrillation. J Int Med Res. 42:224–230. 2014. View Article : Google Scholar
|
|
37
|
Nakano Y, Niida S, Dote K, Takenaka S,
Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M and
Chayama K: Matrix metalloproteinase-9 contributes to human atrial
remodeling during atrial fibrillation. J Am Coll Cardiol.
43:818–825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu G, Wang S, Cheng M, Peng B, Liang J,
Huang H, Jiang X, Zhang L, Yang B, Cha Y, et al: The serum matrix
metalloproteinase-9 level is an independent predictor of recurrence
after ablation of persistent atrial fibrillation. Clinics (Sao
Paulo). 71:251–256. 2016. View Article : Google Scholar
|
|
39
|
Liu Y, Xu B, Wu N, Xiang Y, Wu L, Zhang M,
Wang J, Chen X, Li Y and Zhong L: Association of MMPs and TIMPs
with the occurrence of atrial fibrillation: A systematic review and
meta-analysis. Can J Cardiol. 32:803–813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Molvin J, Jujic A, Melander O, Pareek M,
Råstam L, Lindblad U, Daka B, Leosdottir M, Nilsson P, Olsen M and
Magnusson M: Exploration of pathophysiological pathways for
incident atrial fibrillation using a multiplex proteomic chip. Open
Heart. 7:e0011902020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Morikawa M, Derynck R and Miyazono K:
TGF-β and the TGF-β family: Context-dependent roles in cell and
tissue physiology. Cold Spring Harb Perspect Biol. 8:a0218732016.
View Article : Google Scholar
|
|
42
|
Biernacka A, Dobaczewski M and
Frangogiannis NG: TGF-beta signaling in fibrosis. Growth Factors.
29:196–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Heldin CH, Miyazono K and ten Dijke P:
TGF-beta signalling from cell membrane to nucleus through SMAD
proteins. Nature. 390:465–471. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Euler-Taimor G and Heger J: The complex
pattern of SMAD signaling in the cardiovascular system. Cardiovasc
Res. 69:15–25. 2006. View Article : Google Scholar
|
|
45
|
Zhang D, Chen X, Wang Q, Wu S, Zheng Y and
Liu X: Role of the MAPKs/TGF-β1/TRAF6 signaling pathway in
postoperative atrial fibrillation. PLoS One. 12:e01737592017.
View Article : Google Scholar
|
|
46
|
Chang SH, Yeh YH, Lee JL, Hsu YJ, Kuo CT
and Chen WJ: Transforming growth factor-β-mediated CD44/STAT3
signaling contributes to the development of atrial fibrosis and
fibrillation. Basic Res Cardiol. 112:582017. View Article : Google Scholar
|
|
47
|
Liu LJ, Yao FJ, Lu GH, Xu CG, Xu Z, Tang
K, Cheng YJ, Gao XR and Wu SH: The role of the Rho/ROCK pathway in
Ang II and TGF-β1-induced atrial remodeling. PLoS One.
11:e01616252016. View Article : Google Scholar
|
|
48
|
Yang Z and Wang H: Increased expression of
the TSP-1/TGF-β/MMP-9 axis in atrial fibrillation related to
rheumatic heart disease. Int J Clin Exp Med. 11:5699–5706.
2018.
|
|
49
|
Yeh YH, Kuo CT, Chan TH, Chang GJ, Qi XY,
Tsai F, Nattel S and Chen WJ: Transforming growth factor-β and
oxidative stress mediate tachycardia-induced cellular remodelling
in cultured atrial-derived myocytes. Cardiovasc Res. 91:62–70.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Patel S, Rauf A, Khan H and Abu-Izneid T:
Renin-angiotensinaldosterone (RAAS): The ubiquitous system for
homeostasis and pathologies. Biomed Pharmacother. 94:317–325. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Harada M, Luo X, Qi XY, Tadevosyan A,
Maguy A, Ordog B, Ledoux J, Kato T, Naud P, Voigt N, et al:
Transient receptor potential canonical-3 channel-dependent
fibroblast regulation in atrial fibrillation. Circulation.
126:2051–2064. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu L, Geng J, Zhao H, Yun F, Wang X, Yan
S, Ding X, Li W, Wang D, Li J, et al: Valsartan reduced atrial
fibrillation susceptibility by inhibiting atrial parasympathetic
remodeling through MAPKs/neurturin pathway. Cell Physiol Biochem.
36:2039–2050. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Harada M, Van Wagoner DR and Nattel S:
Role of inflammation in atrial fibrillation pathophysiology and
management. Circ J. 79:495–502. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gu J, Liu X, Wang QX, Tan HW, Guo M, Jiang
WF and Zhou L: Angiotensin II increases CTGF expression via
MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. Exp Cell Res.
318:2105–2115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nouet S and Nahmias C: Signal transduction
from the angiotensin II AT2 receptor. Trends Endocrinol Metab.
11:1–6. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sakabe M, Fujiki A, Nishida K, Sugao M,
Nagasawa H, Tsuneda T, Mizumaki K and Inoue H: Enalapril prevents
perpetuation of atrial fibrillation by suppressing atrial fibrosis
and over-expression of connexin43 in a canine model of atrial
pacing-induced left ventricular dysfunction. J Cardiovasc
Pharmacol. 43:851–859. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li D, Shinagawa K, Pang L, Leung TK,
Cardin S, Wang Z and Nattel S: Effects of angiotensin-converting
enzyme inhibition on the development of the atrial fibrillation
substrate in dogs with ventricular tachypacing-induced congestive
heart failure. Circulation. 104:2608–2614. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lavall D, Selzer C, Schuster P, Lenski M,
Adam O, Schäfers HJ, Böhm M and Laufs U: The mineralocorticoid
receptor promotes fibrotic remodeling in atrial fibrillation. J
Biol Chem. 289:6656–6668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tsai CF, Yang SF, Chu HJ and Ueng KC:
Cross-talk between mineralocorticoid receptor/angiotensin II type 1
receptor and mitogen-activated protein kinase pathways underlies
aldosterone-induced atrial fibrotic responses in HL-1
cardiomyocytes. Int J Cardiol. 169:17–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bruins P, te Velthuis H, Yazdanbakhsh AP,
Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman
L, Trouwborst A and Hack CE: Activation of the complement system
during and after cardiopulmonary bypass surgery: Postsurgery
activation involves C-reactive protein and is associated with
postoperative arrhythmia. Circulation. 96:3542–3548. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hu YF, Chen YJ, Lin YJ and Chen SA:
Inflammation and the pathogenesis of atrial fibrillation. Nat Rev
Cardiol. 12:230–243. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Huang CX, Liu Y, Xia WF, Tang YH and Huang
H: Oxidative stress: A possible pathogenesis of atrial
fibrillation. Med Hypotheses. 72:466–467. 2009. View Article : Google Scholar
|
|
63
|
Sovari AA and Dudley SC Jr: Reactive
oxygen species-targeted therapeutic interventions for atrial
fibrillation. Front Physiol. 3:3112012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Görlach A, Bertram K, Hudecova S and
Krizanova O: Calcium and ROS: A mutual interplay. Redox Biol.
6:260–271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Youn JY, Zhang J, Zhang Y, Chen H, Liu D,
Ping P, Weiss JN and Cai H: Oxidative stress in atrial
fibrillation: An emerging role of NADPH oxidase. J Mol Cell
Cardiol. 62:72–79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Nattel S and Harada M: Atrial remodeling
and atrial fibrillation: Recent advances and translational
perspectives. J Am Coll Cardiol. 63:2335–2345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sirish P, Li N, Timofeyev V, Zhang XD,
Wang L, Yang J, Lee KS, Bettaieb A, Ma SM, Lee JH, et al: Molecular
mechanisms and new treatment paradigm for atrial fibrillation. Circ
Arrhythm Electrophysiol. 9:e0037212016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mazurek T, Zhang L, Zalewski A, Mannion
JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson
AG, et al: Human epicardial adipose tissue is a source of
inflammatory mediators. Circulation. 108:2460–2466. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Abe I, Teshima Y, Kondo H, Kaku H, Kira S,
Ikebe Y, Saito S, Fukui A, Shinohara T, Yufu K, et al: Association
of fibrotic remodeling and cytokines/chemokines content in
epicardial adipose tissue with atrial myocardial fibrosis in
patients with atrial fibrillation. Heart Rhythm. 15:1717–1727.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Venteclef N, Guglielmi V, Balse E, Gaborit
B, Cotillard A, Atassi F, Amour J, Leprince P, Dutour A, Clément K
and Hatem SN: Human epicardial adipose tissue induces fibrosis of
the atrial myocardium through the secretion of adipo-fibrokines.
Eur Heart J. 36:795–805a. 2015. View Article : Google Scholar
|
|
71
|
Wang Q, Wang X, Yin L, Wang J, Shen H, Gao
Y, Min J, Zhang Y and Wang Z: Human epicardial adipose tissue cTGF
expression is an independent risk factor for atrial fibrillation
and highly associated with atrial fibrosis. Sci Rep. 8:35852018.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li Y, Jian Z, Yang ZY, Chen L, Wang XF, Ma
RY and Xiao YB: Increased expression of connective tissue growth
factor and transforming growth factor-beta-1 in atrial myocardium
of patients with chronic atrial fibrillation. Cardiology.
124:233–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liao CH, Akazawa H, Tamagawa M, Ito K,
Yasuda N, Kudo Y, Yamamoto R, Ozasa Y, Fujimoto M, Wang P, et al:
Cardiac mast cells cause atrial fibrillation through
PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J
Clin Invest. 120:242–253. 2010. View Article : Google Scholar
|
|
74
|
Chen Y, Surinkaew S, Naud P, Qi XY, Gillis
MA, Shi YF, Tardif JC, Dobrev D and Nattel S: JAK-STAT signalling
and the atrial fibrillation promoting fibrotic substrate.
Cardiovasc Res. 113:310–320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tuuminen R, Nykänen AI, Krebs R, Soronen
J, Pajusola K, Keränen MA, Koskinen PK, Alitalo K and Lemström KB:
PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic
rejection in rat cardiac allografts. Arterioscler Thromb Vasc Biol.
29:691–698. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li PF, He RH, Shi SB, Li R, Wang QT, Rao
GT and Yang B: Modulation of miR-10a-mediated TGF-β1/Smads
signaling affects atrial fibrillation-induced cardiac fibrosis and
cardiac fibroblast proliferation. Biosci Rep. 39:BSR201819312019.
View Article : Google Scholar
|
|
77
|
Thum T, Gross C, Fiedler J, Fischer T,
Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et
al: MicroRNA-21 contributes to myocardial disease by stimulating
MAP kinase signalling in fibroblasts. Nature. 456:980–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Adam O, Löhfelm B, Thum T, Gupta SK, Puhl
SL, Schäfers HJ, Böhm M and Laufs U: Role of miR-21 in the
pathogenesis of atrial fibrosis. Basic Res Cardiol. 107:2782012.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
He X, Zhang K, Gao X, Li L, Tan H, Chen J
and Zhou Y: Rapid atrial pacing induces myocardial fibrosis by
down-regulating Smad7 via microRNA-21 in rabbit. Heart Vessels.
31:1696–1708. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wang Y, Cai H, Li H, Gao Z and Song K:
Atrial overexpression of microRNA-27b attenuates angiotensin
II-induced atrial fibrosis and fibrillation by targeting ALK5. Hum
Cell. 31:251–260. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Chen Y, Wakili R, Xiao J, Wu CT, Luo X,
Clauss S, Dawson K, Qi X, Naud P, Shi YF, et al: Detailed
characterization of microRNA changes in a canine heart failure
model: Relationship to arrhythmogenic structural remodeling. J Mol
Cell Cardiol. 77:113–124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Shantsila E, Shantsila A, Blann AD and Lip
GY: Left ventricular fibrosis in atrial fibrillation. Am J Cardiol.
111:996–1001. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
White SK, Sado DM, Fontana M, Banypersad
SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ,
Sheikh AM, et al: T1 mapping for myocardial extracellular volume
measurement by CMR: bolus only versus primed infusion technique.
JACC Cardiovasc Imaging. 6:955–962. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Neilan TG, Shah RV, Abbasi SA, Farhad H,
Groarke JD, Dodson JA, Coelho-Filho O, McMullan CJ, Heydari B,
Michaud GF, et al: The incidence, pattern, and prognostic value of
left ventricular myocardial scar by late gadolinium enhancement in
patients with atrial fibrillation. J Am Coll Cardiol. 62:2205–2214.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ambale-Venkatesh B and Lima JA: Cardiac
MRI: A central prognostic tool in myocardial fibrosis. Nat Rev
Cardiol. 12:18–29. 2015. View Article : Google Scholar
|
|
86
|
Flett AS, Hayward MP, Ashworth MT, Hansen
MS, Taylor AM, Elliott PM, McGregor C and Moon JC: Equilibrium
contrast cardiovascular magnetic resonance for the measurement of
diffuse myocardial fibrosis: Preliminary validation in humans.
Circulation. 122:138–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kammerlander AA, Marzluf BA, Zotter-Tufaro
C, Aschauer S, Duca F, Bachmann A, Knechtelsdorfer K, Wiesinger M,
Pfaffenberger S, Greiser A, et al: T1 mapping by CMR imaging: From
histological validation to clinical implication. JACC Cardiovasc
Imaging. 9:14–23. 2016. View Article : Google Scholar
|
|
88
|
Ling LH, Kistler PM, Ellims AH, Iles LM,
Lee G, Hughes GL, Kalman JM, Kaye DM and Taylor AJ: Diffuse
ventricular fibrosis in atrial fibrillation: Noninvasive evaluation
and relationships with aging and systolic dysfunction. J Am Coll
Cardiol. 60:2402–2408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Neilan TG, Mongeon FP, Shah RV,
Coelho-Filho O, Abbasi SA, Dodson JA, McMullan CJ, Heydari B,
Michaud GF, John RM, et al: Myocardial extracellular volume
expansion and the risk of recurrent atrial fibrillation after
pulmonary vein isolation. JACC Cardiovasc Imaging. 7:1–11. 2014.
View Article : Google Scholar
|
|
90
|
McLellan AJ, Ling LH, Azzopardi S, Ellims
AH, Iles LM, Sellenger MA, Morton JB, Kalman JM, Taylor AJ and
Kistler PM: Diffuse ventricular fibrosis measured by T1 mapping on
cardiac MRI predicts success of catheter ablation for atrial
fibrillation. Circ Arrhythm Electrophysiol. 7:834–840. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Guichard JB, Xiong F, Qi XY, L'Heureux N,
Hiram R, Xiao J, Naud P, Tardif JC, Costa AD and Nattel S: Role of
atrial arrhythmia and ventricular response in atrial fibrillation
induced atrial remodeling. Cardiovasc Res. Jan 24–2020.Epub ahead
of print. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Sasaki N, Okumura Y, Watanabe I, Nagashima
K, Sonoda K, Kogawa R, Takahashi K, Iso K, Ohkubo K, Nakai T, et
al: Transthoracic echocardiographic backscatter-based assessment of
left atrial remodeling involving left atrial and ventricular
fibrosis in patients with atrial fibrillation. Int J Cardiol.
176:1064–1066. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Avitall B, Bi J, Mykytsey A and Chicos A:
Atrial and ventricular fibrosis induced by atrial fibrillation:
Evidence to support early rhythm control. Heart Rhythm. 5:839–845.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Prabhu S, Costello BT, Taylor AJ, Gutman
SJ, Voskoboinik A, McLellan AJA, Peck KY, Sugumar H, Iles L, Pathik
B, et al: Regression of diffuse ventricular fibrosis following
restoration of sinus rhythm with catheter ablation in patients with
atrial fibrillation and systolic dysfunction: A substudy of the
CAMERA MRI trial. JACC Clin Electrophysiol. 4:999–1007. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Schoonderwoerd BA, Smit MD, Pen L and Van
Gelder IC: New risk factors for atrial fibrillation: Causes of
'not-so-lone atrial fibrillation'. Europace. 10:668–673. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Iwasaki YK, Kato T, Xiong F, Shi YF, Naud
P, Maguy A, Mizuno K, Tardif JC, Comtois P and Nattel S: Atrial
fibrillation promotion with long-term repetitive obstructive sleep
apnea in a rat model. J Am Coll Cardiol. 64:2013–2023. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Neilan TG, Farhad H, Dodson JA, Shah RV,
Abbasi SA, Bakker JP, Michaud GF, van der Geest R, Blankstein R,
Steigner M, et al: Effect of sleep apnea and continuous positive
airway pressure on cardiac structure and recurrence of atrial
fibrillation. J Am Heart Assoc. 2:e0004212013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Pathak RK, Mahajan R, Lau DH and Sanders
P: The implications of obesity for cardiac arrhythmia mechanisms
and management. Can J Cardiol. 31:203–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wijesurendra RS and Casadei B: Atrial
fibrillation: Effects beyond the atrium? Cardiovasc Res.
105:238–247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Rahmutula D, Marcus GM, Wilson EE, Ding
CH, Xiao Y, Paquet AC, Barbeau R, Barczak AJ, Erle DJ and Olgin JE:
Molecular basis of selective atrial fibrosis due to overexpression
of transforming growth factor-β1. Cardiovasc Res. 99:769–779. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Xiao HD, Fuchs S, Campbell DJ, Lewis W,
Dudley SC Jr, Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR
and Bernstein KE: Mice with cardiac-restricted
angiotensin-converting enzyme (ACE) have atrial enlargement,
cardiac arrhythmia, and sudden death. Am J Pathol. 165:1019–1032.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bauer P, regitz-zagrosek V, Kallisch H,
Linz W, Schoelkens B, Hildebrandt AG and Fleck E: Myocardial
angiotensin receptor type 1 gene expression in a rat model of
cardiac volume overload. Basic Res Cardiol. 92:139–146. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Yeh YH, Kuo CT, Chang GJ, Qi XY, Nattel S
and Chen WJ: Nicotinamide adenine dinucleotide phosphate oxidase 4
mediates the differential responsiveness of atrial versus
ventricular fibroblasts to transforming growth factor-β. Circ
Arrhythm Electrophysiol. 6:790–798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Daccarett M, Badger TJ, Akoum N, Burgon
NS, Mahnkopf C, Vergara G, Kholmovski E, McGann CJ, Parker D,
Brachmann J, et al: Association of left atrial fibrosis detected by
delayed-enhancement magnetic resonance imaging and the risk of
stroke in patients with atrial fibrillation. J Am Coll Cardiol.
57:831–838. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Akoum N, Fernandez G, Wilson B, Mcgann C,
Kholmovski E and Marrouche N: Association of atrial fibrosis
quantified using LGE-MRI with atrial appendage thrombus and
spontaneous contrast on transesophageal echocardiography in
patients with atrial fibrillation. J Cardiovasc Electrophysiol.
24:1104–1109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
King JB, Azadani PN, Suksaranjit P, Bress
AP, Witt DM, Han FT, Chelu MG, Silver MA, Biskupiak J, Wilson BD,
et al: Left atrial fibrosis and risk of cerebrovascular and
cardiovascular events in patients with atrial fibrillation. J Am
Coll Cardiol. 70:1311–1321. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Disertori M, Quintarelli S, Grasso M,
Pilotto A, Narula N, Favalli V, Canclini C, Diegoli M, Mazzola S,
Marini M, et al: Autosomal recessive atrial dilated cardiomyopathy
with standstill evolution associated with mutation of natriuretic
peptide precursor A. Circ Cardiovasc Genet. 6:27–36. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Fonseca AC, Alves P, Inácio N, Marto JP,
Viana-Baptista M, Pinho-E-Melo T, Ferro JM and Almeida AG: Patients
with undetermined stroke have increased atrial fibrosis: A cardiac
magnetic resonance imaging study. Stroke. 49:734–737. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Tandon K, Tirschwell D, Longstreth WT Jr,
Smith B and Akoum N: Embolic stroke of undetermined source
correlates to atrial fibrosis without atrial fibrillation.
Neurology. 93:e381–e387. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Spronk HM, De Jong AM, Verheule S, De Boer
HC, Maass AH, Lau DH, Rienstra M, van Hunnik A, Kuiper M, Lumeij S,
et al: Hypercoagulability causes atrial fibrosis and promotes
atrial fibrillation. Eur Heart J. 38:38–50. 2017. View Article : Google Scholar
|
|
111
|
D'Souza A, Butcher KS and Buck BH: The
multiple causes of stroke in atrial fibrillation: Thinking broadly.
Can J Cardiol. 34:1503–1511. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cai H, Li Z, Goette A, Mera F, Honeycutt
C, Feterik K, Wilcox JN, Dudley SC Jr, Harrison DG and Langberg JJ:
Downregulation of endocardial nitric oxide synthase expression and
nitric oxide production in atrial fibrillation: Potential
mechanisms for atrial thrombosis and stroke. Circulation.
106:2854–2858. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Friedrichs K, Klinke A and Baldus S:
Inflammatory pathways underlying Atrial Fibrillation. Trends Mol
Med. 17:556–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Korantzopoulos P, Letsas K, Fragakis N,
Tse G and Liu T: Oxidative stress and atrial fibrillation: An
update. Free Radic Res. 52:1199–1209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Cao H, Wang J, Xi L, Røe OD, Chen Y and
Wang D: Dysregulated atrial gene expression of
osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK
ligand axis in the development and progression of atrial
fibrillation. Circ J. 75:2781–2788. 2011. View Article : Google Scholar
|
|
116
|
Pinto A, Tuttolomondo A, Casuccio A, Di
Raimondo D, Di Sciacca R, Arnao V and Licata G: Immuno-inflammatory
predictors of stroke at follow-up in patients with chronic
non-valvular atrial fibrillation (NVAF). Clin Sci (Lond).
116:781–789. 2009. View Article : Google Scholar
|
|
117
|
Li J, Solus J, Chen Q, Rho YH, Milne G,
Stein CM and Darbar D: Role of inflammation and oxidative stress in
atrial fibrillation. Heart Rhythm. 7:438–444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Calvo D, Filgueiras-Rama D and Jalife J:
Mechanisms and drug development in atrial fibrillation. Pharmacol
Rev. 70:505–525. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Sardar MR, Saeed W and Kowey PR:
Antiarrhythmic drug therapy for atrial fibrillation. Heart Fail
Clin. 12:205–221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Burashnikov A and Antzelevitch C: Novel
pharmacological targets for the rhythm control management of atrial
fibrillation. Pharmacol Ther. 132:300–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Novo G, Guttilla D, Fazio G, Cooper D and
Novo S: The role of the renin-angiotensin system in atrial
fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J
Clin Pharmacol. 66:345–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Li Y, Li W, Yang B, Han W, Dong D, Xue J,
Li B, Yang S and Sheng L: Effects of Cilazapril on atrial
electrical, structural and functional remodeling in atrial
fibrillation dogs. J Electrocardiol. 40:100.e1–e6. 2007. View Article : Google Scholar
|
|
123
|
Belluzzi F, Sernesi L, Preti P, Salinaro
F, Fonte ML and Perlini S: Prevention of recurrent lone atrial
fibrillation by the angiotensin-II converting enzyme inhibitor
ramipril in normotensive patients. J Am Coll Cardiol. 53:24–29.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Akashiba A, Ono H, Ono Y, Ishimitsu T and
Matsuoka H: Valsartan improves L-NAME-exacerbated cardiac fibrosis
with TGF-ß inhibition and apoptosis induction in spontaneously
hypertensive rats. J Cardiol. 52:239–246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kumagai K, Nakashima H, Urata H, Gondo N,
Arakawa K and Saku K: Effects of angiotensin II type 1 receptor
antagonist on electrical and structural remodeling in atrial
fibrillation. J Am Coll Cardiol. 41:2197–2204. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Nomura M, Kawano T, Nakayasu K and Nakaya
Y: The effects of losartan on signal-averaged P wave in patients
with atrial fibrillation. Int J Cardiol. 126:21–27. 2008.
View Article : Google Scholar
|
|
127
|
Takemoto Y, Ramirez RJ, Kaur K,
Salvador-Montañés O, Ponce-Balbuena D, Ramos-Mondragón R, Ennis SR,
Guerrero-Serna G, Berenfeld O and Jalife J: Eplerenone reduces
atrial fibrillation burden without preventing atrial electrical
remodeling. J Am Coll Cardiol. 70:2893–2905. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Neefs J, van den Berg NW, Limpens J,
Berger WR, Boekholdt SM, Sanders P and de Groot JR: Aldosterone
pathway blockade to prevent atrial fibrillation: A systematic
review and meta-analysis. Int J Cardiol. 231:155–161. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Rienstra M, Hobbelt AH, Alings M, Tijssen
JGP, Smit MD, Brügemann J, Geelhoed B, Tieleman RG, Hillege HL,
Tukkie R, et al: Targeted therapy of underlying conditions improves
sinus rhythm maintenance in patients with persistent atrial
fibrillation: Results of the RACE 3 trial. Eur Heart J.
39:2987–2896. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Schneider MP, Hua TA, Böhm M, Wachtell K,
Kjeldsen SE and Schmieder RE: Prevention of atrial fibrillation by
Renin-Angiotensin system inhibition a meta-analysis. J Am Coll
Cardiol. 55:2299–2307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
European Heart Rhythm Association;
European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof
P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC,
Al-Attar N, et al: Guidelines for the management of atrial
fibrillation: The task force for the management of atrial
fibrillation of the European society of cardiology (ESC). Eur Heart
J. 31:2369–2429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chaugai S, Meng WY and Ali Sepehry A:
Effects of RAAS blockers on atrial fibrillation prophylaxis: An
updated systematic review and meta-analysis of randomized
controlled trials. J Cardiovasc Pharmacol Ther. 21:388–404. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
GISSI-AF Investigators; Disertori M,
Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci
D, Di Pasquale G and Tognoni G: Valsartan for prevention of
recurrent atrial fibrillation. N Engl J Med. 360:1606–1617. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Tveit A, Grundvold I, Olufsen M, Seljeflot
I, Abdelnoor M, Arnesen H and Smith P: Candesartan in the
prevention of relapsing atrial fibrillation. Int J Cardiol.
120:85–91. 2007. View Article : Google Scholar
|
|
135
|
Shiroshita-Takeshita A, Brundel BJ,
Burstein B, Leung TK, Mitamura H, Ogawa S and Nattel S: Effects of
simvastatin on the development of the atrial fibrillation substrate
in dogs with congestive heart failure. Cardiovasc Res. 74:75–84.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Kuhn EW, Liakopoulos OJ, Stange S, Deppe
AC, Slottosch I, Choi YH and Wahlers T: Preoperative statin therapy
in cardiac surgery: A meta-analysis of 90,000 patients. Eur J
Cardiothorac Surg. 45:17–26. 2014. View Article : Google Scholar
|
|
137
|
Salvador-Montañés O, Gómez-Gallanti A,
Garofalo D, Noujaim SF, Peinado R and Filgueiras-Rama D:
Polyunsaturated Fatty acids in atrial fibrillation: Looking for the
proper candidates. Front Physiol. 3:3702012. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Lee KW, Everett TH IV, Rahmutula D, Guerra
JM, Wilson E, Ding C and Olgin JE: Pirfenidone prevents the
development of a vulnerable substrate for atrial fibrillation in a
canine model of heart failure. Circulation. 114:1703–1712. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Anderson JL, Halperin JL, Albert NM,
Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS,
Kovacs RJ, et al: Management of patients with atrial fibrillation
(compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS
recommendations): A report of the American college of
cardiology/American heart association task force on practice
guidelines. J Am Coll Cardiol. 61:1935–1944. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Holmqvist F, Kesek M, Englund A,
Blomström-Lundqvist C, Karlsson LO, Kennebäck G, Poçi D, Samo-Ayou
R, Sigurjónsdóttir R, Ringborn M, et al: A decade of catheter
ablation of cardiac arrhythmias in Sweden: Ablation practices and
outcomes. Eur Heart J. 40:820–830. 2019. View Article : Google Scholar :
|
|
141
|
Kottkamp H: Human atrial fibrillation
substrate: Towards a specific fibrotic atrial cardiomyopathy. Eur
Heart J. 34:2731–2738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Kottkamp H and Schreiber D: The substrate
in 'early persistent' atrial fibrillation: Arrhythmia induced, risk
factor induced, or from a specific fibrotic atrial cardiomyopathy?
JACC Clin Electrophysiol. 2:140–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Oakes RS, Badger TJ, Kholmovski EG, Akoum
N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM,
et al: Detection and quantification of left atrial structural
remodeling with delayed-enhancement magnetic resonance imaging in
patients with atrial fibrillation. Circulation. 119:1758–1767.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Rolf S, Kircher S, Arya A, Eitel C, Sommer
P, Richter S, Gaspar T, Bollmann A, Altmann D, Piedra C, et al:
Tailored atrial substrate modification based on low-voltage areas
in catheter ablation of atrial fibrillation. Circ Arrhythm
Electrophysiol. 7:825–833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Kapa S, Desjardins B, Callans DJ,
Marchlinski FE and Dixit S: Contact electroanatomic mapping derived
voltage criteria for characterizing left atrial scar in patients
undergoing ablation for atrial fibrillation. J Cardiovasc
Electrophysiol. 25:1044–1052. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Marrouche NF, Wilber D, Hindricks G, Jais
P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, et
al: Association of atrial tissue fibrosis identified by delayed
enhancement MRI and atrial fibrillation catheter ablation: The
DECAAF study. JAMA. 311:498–506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Canpolat U, Oto A, Hazırolan T, Sunman H,
Yorgun H, Şahiner L, Kaya EB and Aytemir K: A prospective DE-MRI
study evaluating the role of TGF-β1 in left atrial fibrosis and
implications for outcomes of cryoballoon-based catheter ablation:
New insights into primary fibrotic atriocardiomyopathy. J
Cardiovasc Electrophysiol. 26:251–259. 2015. View Article : Google Scholar
|
|
148
|
McGann C, Akoum N, Patel A, Kholmovski E,
Revelo P, Damal K, Wilson B, Cates J, Harrison A, Ranjan R, et al:
Atrial fibrillation ablation outcome is predicted by left atrial
remodeling on MRI. Circ Arrhythm Electrophysiol. 7:23–30. 2014.
View Article : Google Scholar :
|
|
149
|
Stiles MK, John B, Wong CX, Kuklik P,
Brooks AG, Lau DH, Dimitri H, Roberts-Thomson KC, Wilson L, De
Sciscio P, et al: Paroxysmal lone atrial fibrillation is associated
with an abnormal atrial substrate: Characterizing the 'second
factor'. J Am Coll Cardiol. 53:1182–1191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Kottkamp H, Berg J, Bender R, Rieger A and
Schreiber D: Box isolation of fibrotic areas (BIFA): A
patient-tailored substrate modification approach for ablation of
atrial fibrillation. J Cardiovasc Electrophysiol. 27:22–30. 2016.
View Article : Google Scholar
|
|
151
|
Yamaguchi T, Tsuchiya T, Nakahara S, Fukui
A, Nagamoto Y, Murotani K, Eshima K and Takahashi N: Efficacy of
left atrial voltage-based catheter ablation of persistent atrial
fibrillation. J Cardiovasc Electrophysiol. 27:1055–1063. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yagishita A, Gimbel JR, DE Oliveira S,
Manyam H, Sparano D, Cakulev I, Mackall J and Arruda M: Long-term
outcome of left atrial voltage-guided substrate ablation during
atrial fibrillation: A novel adjunctive ablation strategy. J
Cardiovasc Electrophysiol. 28:147–155. 2017. View Article : Google Scholar
|
|
153
|
Jadidi AS, Lehrmann H, Keyl C, Sorrel J,
Markstein V, Minners J, Park CI, Denis A, Jaïs P, Hocini M, et al:
Ablation of persistent atrial fibrillation targeting low-voltage
areas with selective activation characteristics. Circ Arrhythm
Electrophysiol. 9:e0029622016.PubMed/NCBI
|
|
154
|
Yang G, Yang B, Wei Y, Zhang F, Ju W, Chen
H, Li M, Gu K, Lin Y, Wang B, et al: Catheter ablation of
nonparoxysmal atrial fibrillation using electrophysiologically
guided substrate modification during sinus rhythm after pulmonary
vein isolation. Circ Arrhythm Electrophysiol. 9:e0033822016.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Kottkamp H, Schreiber D, Moser F and
Rieger A: Therapeutic approaches to atrial fibrillation ablation
targeting atrial fibrosis. JACC Clin Electrophysiol. 3:643–653.
2017. View Article : Google Scholar
|
|
156
|
Jadidi AS, Cochet H, Shah AJ, Kim SJ,
Duncan E, Miyazaki S, Sermesant M, Lehrmann H, Lederlin M, Linton
N, et al: Inverse relationship between fractionated electrograms
and atrial fibrosis in persistent atrial fibrillation: Combined
magnetic resonance imaging and high-density mapping. J Am Coll
Cardiol. 62:802–812. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Gal P and Marrouche NF: Magnetic resonance
imaging of atrial fibrosis: Redefining atrial fibrillation to a
syndrome. Eur Heart J. 38:14–19. 2017. View Article : Google Scholar
|
|
158
|
Fochler F, Yamaguchi T, Kheirkahan M,
Kholmovski EG, Morris AK and Marrouche NF: Late gadolinium
enhancement magnetic resonance imaging guided treatment of
post-atrial fibrillation ablation recurrent arrhythmia. Circ
Arrhythm Electrophysiol. 12:e0071742019. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Boyle PM, Zghaib T, Zahid S, Ali RL, Deng
D, Franceschi WH, Hakim JB, Murphy MJ, Prakosa A, Zimmerman SL, et
al: Computationally guided personalized targeted ablation of
persistent atrial fibrillation. Nat Biomed Eng. 3:870–879. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Sohns C and Marrouche NF: Atrial
fibrillation and cardiac fibrosis. Eur Heart J. 41:1123–1131. 2020.
View Article : Google Scholar
|
|
161
|
Kottkamp H, Bender R and Berg J: Catheter
ablation of atrial fibrillation: How to modify the substrate? J Am
Coll Cardiol. 65:196–206. 2015. View Article : Google Scholar : PubMed/NCBI
|
